177Lu-girentuximab is a radiopharmaceutical monoclonal antibody that targets carbonic anhydrase IX (CAIX), a cell surface protein expressed in ccRCC [62]. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.